ArticleParasites & vectors2026
Preliminary study on expression and functions of Toxoplasma gondii SRS67 and SRS20A proteins.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundToxoplasma gondii surface proteins play critical roles in parasite invasion, proliferation, and host immune modulation, and represent promising targets for anti-toxoplasmosis intervention. SRS67 and SRS20A are poorly characterized surface proteins of T. gondii, and their biological functions and host regulatory effects remain largely unclear.
methodsIn the present study, we prepared recombinant SRS67 and SRS20A proteins and generated corresponding polyclonal antibodies to explore their functional characteristics and protective potentials.
resultsImmunofluorescence analysis localized both proteins as punctate signals surrounding the parasite membrane, indicating their involvement in surface-associated biological processes. In vitro phenotypic assays demonstrated that the prepared polyclonal antibodies significantly inhibited host cell invasion and intracellular proliferation of T. gondii. In vivo animal experiments further showed that antibody treatment effectively alleviated T. gondii-caused pathological injuries in mice. In the acute RH infection model, single or combined protein immunization increased the survival rate of mice by approximately 60%, and combined immunization delayed mortality by 1-2 days. In chronic PRU infection, antibody intervention reduced brain cyst burden by over 85% and markedly attenuated meningeal thickening and neuronal necrosis. Mechanistically, SRS67 upregulated the expression of Th1 cytokines (TNF-α, IL-18) during acute infection, while both proteins downregulated IFN-γ to limit excessive immune-mediated tissue damage. The elevated glutathione (GSH) level suggested the participation of these proteins in antioxidant regulation. During chronic infection, combined immunization synergistically enhanced superoxide dismutase (SOD) activity to resist oxidative stress, and decreased IFN-γ expression contributed to the maintenance of immune homeostasis.
conclusionsCollectively, this study systematically characterizes the biological functions of SRS67 and SRS20A, and demonstrates that their polyclonal antibodies exert potent inhibitory effects against T. gondii infection by directly blocking parasite biological behaviors and indirectly regulating host immune responses and antioxidant status. Our findings provide novel insights into the functional mechanisms of SRS family proteins and support the development of SRS-targeted anti-Toxoplasma strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.